MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'insider trading'. Sat, 03 Sep 2011 02:50:47 +0100 http://www.medworm.com/index.php?rid=4780487&cid=t_147427_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FE701Bp9oFBU%2F The FDA Bad Ad program, in which someone drops a dime on offending promotional materials, has turned up another violator. The latest is Three Rivers Pharmaceuticals, which is headed by former ImClone Systems ceo and convicted inside trader, Sam Waksal. In a warning letter posted on the FDA web site, Sam & Co. are taken to task for a host of offenses in connection with a Statgram communication for the Infergen hepatitis c treatment - omitting and minimizing risk info; broadening the indication and omitting important facts; overstating efficiacy; making unsubstantiated claims, and failing to provide adequate directions for use. In short, Three Rivers did almost nothing right. Topping the list: the Statgram claims docs can obtain additional prescribing info, including the safety profile ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4780487 Tue, 03 May 2011 12:34:48 +0100 4780487 http://www.medworm.com/index.php?rid=4653601&cid=t_147427_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fd412WCNP6vY%2F An FDA chemist named Cheng Yi Liang was charged today by the US Securities and Exchange Commission with insider trading on confidential info about upcoming announcements of 27 different FDA approval decisions involving 19 publicly traded companies and generated more than $3.6 million in illegal profits for himself. And would you believe that he avoided incurring any losses? Some of the FDA announcements involved approval of new drugs while others concerned were negative decisions. In each instance, the SEC says he traded in the same direction as the announcement, but worked hard to disguise his work. Beginning in July 2006, Liang traded in seven brokerage accounts, including six listed in the names of other people, including his 25-year-old (who was also charged) and his 84-year-old mothe... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4653601 Tue, 29 Mar 2011 20:46:19 +0100 4653601 http://www.medworm.com/index.php?rid=4566337&cid=t_147427_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FLVl3LDBcoDM%2F The Massachussets Secretary of the Commonwealth has filed a complaint that accuses a hedge fund of making profits on two pharmaceuticals stock by using insider information. Specifically, Risk Reward Capital Management was charged with using a so-called expert consultant to obtain advance info about an Ariad Pharmaceuticals clinical trial and a forthcoming abstract about a med sold by Questor Pharmaceuticals. According to the complaint, Risk Reward principal investment advisor James Silverman* retained Guidepoint Global for an $80,000 annual fee in exchange for obtaining alleged insider info. He hired the firm in early 2008, after his fund lost 16.9 percent in 2007, which was his first year of operation. Ultimately, Guidepoint arranged for him to meet with 225 experts, about 60 percent of ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4566337 Wed, 09 Mar 2011 19:11:53 +0100 4566337 http://www.medworm.com/index.php?rid=4377789&cid=t_147427_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FaVe4cHW2HSM%2F In a move that some may consider long overdue, more than a dozen of the most prestigious medical journals will consider requiring doctors who submit studies to disclose any payments received from hedge funds and other large investors. The proposal is expected to be discussed at the next annual meeting of The International Committee of Medical Journal Editors, which is scheduled for June, according to a spokeswoman for the New England Journal of Medicine. The possibility follows ongoing concerns about conflicts of interest between researchers and the pharmaceutical industry and the extent to which undisclosed financial relationships may unduly influence medical research and, from there, medical practice. But the issue is also encompassing financial ties to large investors, given the growing... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4377789 Thu, 20 Jan 2011 15:21:05 +0100 4377789 http://www.medworm.com/index.php?rid=4225659&cid=t_147427_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FaUJt6QgUc6g%2F Once again, another work week is about to draw to a close. Although meetings and deadlines loom today, already we are looking ahead to spending time with the short people, a night at the movies, catching up on some reading and promenading with the official Pharmalot mascots. What about you? Anything special planned? Maybe an afternoon nap or a fancy dinner? Well, you could always pay some bills. In any event, here are a few tidbits to peruse while you consider the possibilities. Whatever you do, have a great time and stay safe. See you soon… Pharma Mergers Scrutinized In Insider Trading Probe (Reuters) Merck Pays $500 For SmartCell Diabetes Drugmaker (Bloomberg News) FDA Panel Backs AstraZeneca Thyroid Drug (MedPage Today) Licensing Deal Threatends Cheap AIDS Meds For Poor (The Indep... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4225659 Fri, 03 Dec 2010 12:36:07 +0100 4225659 http://www.medworm.com/index.php?rid=4142714&cid=t_147427_83_f&fid=34856&url=http%3A%2F%2Finsidesurgery.com%2F2010%2F11%2Fsurgeon-turned-banker-dr-chip-skowron-possibly-involved-insider-case%2F Orthopedic surgeon turned hedge fund financier Dr. Chip Skowron’s name is being mentioned in connection with a growing insider trading scandalinvolving FrontPoint Partners. (Source: Inside Surgery) Inside Surgery blogs http://www.medworm.com/rss/comments.php?id=4142714 Sun, 07 Nov 2010 15:59:14 +0100 4142714 http://www.medworm.com/index.php?rid=3925085&cid=t_147427_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FXW-OHW3ZCaI%2F In a lawsuit filed in federal court in Philadelphia, the US Securities and Exchange Commission has charged Jim Self, a pharmaceutical executive, and Stephen Goldfield, a hedge fund manager, with insider trading in connection with the 2007 acquisiton of MedImmune by AstraZeneca. Ultimately, Goldfield made nearly $14 million on his trades, according to the lawsuit. The men allegedly met while attending the Executive MBA program at the Wharton School of Business in the mid-1990’s and, in March 2007, Self exec passed along confidential info about MedImmune. At the time, investment bankers were shopping the biotech to 22 drugmakers and Self had been assigned to evaluate a potential acquisition, according to the lawsuit. In fact, Self was “involved in practically all of the meetings&... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3925085 Wed, 01 Sep 2010 17:38:23 +0100 3925085 http://www.medworm.com/index.php?rid=3404143&cid=t_147427_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FuzDwPCt43xM%2F Top of the morning to you. We are hustling about as we get ready to deliver the short people to various schoolhouses. But as you know, we enjoy challenges. Of course, another challenge beckons - preparing for the day ahead. With meetings and deadlines looming, here are a few items that should help. Good luck, everyone, and keep in touch… UBS Broker Charged In Insider Trading Pharma Case (NBC New York) Biogen And Elan Plan Tysabri-Comparison Study (MarketWatch) Medicare Panel Sees Anemia Drug Risks In Kidney Patients (Reuters) Two AVI BioPharma Directors Won’t Return (press release) Aspirin Use In Unexplained Recurrent Miscarriage Studied (HealthDay) Coffee pix thx to chichcacha flickr creative commons (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3404143 Thu, 25 Mar 2010 11:50:21 +0100 3404143 http://www.medworm.com/index.php?rid=3280194&cid=t_147427_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FHKZg6J3ABc8%2F Samuel Waksal, whose ImClone Systems stock tips landed him and Martha Stewart in federal prison, is getting back into biotech by trying to raise $50 million for a new privately held biopharma company, according to a fund-raising prospectus obtained by TheStreet. Kadmon I LLC, of which Waksal is managing member, would acquire, develop or license new drugs targeting cancer and infectious diseases. Kadmon is also in negotiations to acquire an unidentified drug company to use as its operational base, although binding agreements are not yet in place, according to the prospectus dated Feb. 3, TheStreet writes. Waksal and the others hope to sell a 50 percent stake in Kadmon to investors for $50 million, although the offering could be increased to $175 million if demand exists, according to the p... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3280194 Tue, 16 Feb 2010 22:25:15 +0100 3280194 http://www.medworm.com/index.php?rid=3276080&cid=t_147427_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FNE6gV5D_6iU%2F A former information technology specialist and his wife were ordered to pay more than $4 million after the couple refused to cooperate in an alleged insider-trading lawsuit that was filed three years ago by the U.S. Securities and Exchange Commission. The couple, Shane Suman and Monie Rahman, refused to testify or comply with discovery requests concerning the purchase of Molecular Devices by MDS. The SEC accused them of illegally profiting to the tune of approximately $1 million thanks to Suman’s access to confidential emails prior to the January 2007 offer MDS made for Molecular Devices. Suman, according to court documents, was tipped off to the pending acquisition due to his job, which involved troubleshooting computer problems, and he and his wife quickly placed stock and call opt... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3276080 Tue, 16 Feb 2010 15:41:10 +0100 3276080 http://www.medworm.com/index.php?rid=3167448&cid=t_147427_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F8PvzrHbwJKk%2F The agency alleges that Brooke Wagner, 44, a former vp of corporate communications at Indevus Pharmaceuticals, improperly relied on insider info when he sold shares of the biotech, which is based in Lexington, Ma., in May and June 2008. The SEC claims Wagner sold the stock after learning during a company conference call with the FDA that the agency planned to delay approval for Nebido, a testosterone replacement drug being developed by the company. In its suit, the SEC claims the call took place on May 30 and that Wagner’s trading occurred over the next few days. Ironically, he allegedly assembled Indevus employees three days later that no trading in Indevus stock should take place because it would violate securities laws. The agency alleges he avoided losses of $43,000 by selling th... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3167448 Tue, 12 Jan 2010 18:57:52 +0100 3167448 http://www.medworm.com/index.php?rid=3075767&cid=t_147427_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FXR9H6iErs0s%2F Rise and shine, everyone. Another day awaits. And a busy one is predicted. We will be attending a lengthy meeting ourselves, in fact. While you ponder your own schedules and what-not, here are a few items to help you get started. Hope the day is pleasant and productive…. SEC Probes Drug Mergers For Insider Trading (Wall Street Journal) AstraZeneca Explores Alliances With Competitors (Bloomberg News) Roche Invests Another $71M In China (China Post) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3075767 Thu, 10 Dec 2009 11:25:23 +0100 3075767 http://www.medworm.com/index.php?rid=2939275&cid=t_147427_87_f&fid=36438&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FCato-at-liberty%2F%7E3%2FpYOEzr0p1dU%2F How Washington’s plans may result in even higher executive pay. “In 1993, Congress intervened in corporate compensation and messed things up. Now it’s the White House’s turn.” The case for allowing insider trading: “Want to keep companies honest, make the markets work more efficiently and encourage investors to diversify? Let insiders buy and sell.” Cato v. Heritage on the Patriot Act, Round III: “In hindsight, did Congress and the president react too hastily in 2001 by passing the Patriot Act just weeks after the 9/11 attacks?” Instead of fixing the Patriot Act, President Obama is protecting it. Twenty years later: Why the Berlin Wall fell. Podcast: “Financial Privacy and Freedom” featuring Prince Michael of Liech... Cato-at-liberty blogs http://www.medworm.com/rss/comments.php?id=2939275 Wed, 28 Oct 2009 19:38:20 +0100 2939275 http://www.medworm.com/index.php?rid=1720557&cid=t_147427_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F369928827%2F Do you recognize the man in the photo? Why, it’s none other than Sam Waksal, who became infamous for tipping off Martha Stewart when shares in ImClone Systems, the drugmaker that he founded, were about to take a dive back in 2001. A photographer for The New York Post took this shot of Waksal entering his Bronx, New York, halfway house, where he arrived only last week after serving five years in prison. And apparently, he’s getting VIP treatment - he was given a weekend furlough and looks like he went shopping. He’s holding bags from Smythson, a luxury leather shop in midtown Manhattan. “They blocked off the whole reception area just for him,” a source tells the Post, adding that most inmates wait hours to be processed. “Then the director told everyone e... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1720557 Wed, 20 Aug 2008 12:16:09 +0100 1720557 http://www.medworm.com/index.php?rid=1177897&cid=t_147427_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F222926796%2F Reeling from unrelenting press, Congressional investigations and sagging stock prices, the drugmakers this morning issued a statement saying they “strongly object to mischaracterizations about the Enhance trial” for their Vytorin cholesterol med, and attempt to defend their actions during and after the Jan. 14 release of the controversial study results. A quick recap: the study was designed to measure plaque in neck arteries, but results weren’t released for nearly two years. The drugmakers blame the delay on difficulty reading ultrasound images. But they briefly changed the primary endpoint without consulting their lead investigator; there was no data safety monitoring board, and they appointed an ‘independent’ panel to review the data, but three members had... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1177897 Fri, 25 Jan 2008 13:08:20 +0100 1177897 http://www.medworm.com/index.php?rid=1161231&cid=t_147427_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F219035804%2F Now, the House Energy and Commerce Committee wants to know more about the so-called independent panel formed to review the Vytorin trial data, the study’s Data Safety Monitoring Board, stock sales by Schering-Plough execs and the amount of money spent on Vytorin by the Centers for Medicare and Medicaid Services, given the trial results showed the drug wasn’t more effective than cheap generic versions of Zocor, which is part of the Vytorin combo therapy. The congressmen leading the probe - John Dingell and Bart Stupak, both Democrats from Michigan - sent separate letters today seeking all sorts of info from CMS and Schering-Plough. Already, they’re looking at whether Merck and Schering-Plough concealed or manipulated clinical trial data, given that the release of the Vytor... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1161231 Fri, 18 Jan 2008 19:53:10 +0100 1161231 http://www.medworm.com/index.php?rid=996643&cid=t_147427_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F178172662%2F Another day gets under way. The dog has pooped and one of the short people is already at school. And so the way is clear to provide some interesting items. Hope your day is pleasant…. AstraZeneca Says Cobalt Files To Sell Generic Crestor (Bloomberg News) SEC Charges Former Invitrogen Scientist With Insider Trading (Yahoo/Reuters) Elan Sues Actavis Unit Over ADHD Drug Patents (The Independent) Statins May Reduce Prostate Cancer Relapse Risk (PharmaTimes) Studies Clarify How Tamiflu Affects The Brain (The Daily Yomiuri) Eisai Delays Launch Of New Drugs (Bloomberg News) Dr. Reddy’s Eyes Emerging Markets (The Business Standard) LATE ADDITION: Medco Reports Increased Profits (Yahoo/AP) Share / E-mail (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=996643 Thu, 01 Nov 2007 10:28:19 +0100 996643